BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to treat cancer. Get up to date with the BeiGene hematology pipeline and clinical trials.

Abstract accepted at EHA2023 describing the potential for BCL-2 inhibition in adult patients with mature B-cell malignancies.

Abstract accepted at EHA2023 outlining the results of an interim analysis of an ongoing study evaluating the use of BTKi in combination with established therapies in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Abstract accepted at EHA2023 presenting an updated analysis of a Phase 2 study evaluating the efficacy and safety of a BTKi in combination with an anti-CD20 monoclonal antibody in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

Abstract accepted at EHA2023 presenting the final analysis of a Phase 2 study evaluating the efficacy and safety of BTK inhibition in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).